Dicerna, Ipsen Ink RNAi Drug-Discovery Deal

The companies will combine Dicerna's Dicer-substrate technology with Ipsen's peptide-based targeting vectors, which they said will allow cell-specific, intracellular delivery of the RNAi molecules.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.